Editorial review
Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.
UnitedHealthcare (UHC) covers ketamine therapy only when it takes the form of esketamine, sold as Spravato, the nasal spray the Food and Drug Administration (FDA) approved in 2019 for treatment-resistant depression and for depressive symptoms linked to major depressive disorder with suicidal thoughts. UHC does not routinely cover the compounded ketamine lozenges, troches, or injections that many telehealth clinics prescribe off-label for depression, anxiety, or chronic pain, because those forms lack FDA approval for any psychiatric use and are typically self-administered at home rather than given in a monitored clinical setting.
Your actual coverage still depends on your specific UHC plan, your diagnosis, and whether you meet medical necessity criteria, so verifying directly with UHC before you start treatment matters more than any general rule.
Quick Answer
UnitedHealthcare may cover esketamine (Spravato) for treatment-resistant depression when it's given in a certified clinical setting and your plan's medical necessity criteria, usually including prior authorization and documented failed antidepressant trials, are met. UHC generally does not cover compounded, at-home ketamine lozenges or sublingual troches prescribed through telehealth platforms, since that use is off-label and happens outside the FDA-mandated monitoring structure for esketamine. Exact rules differ between UHC commercial, Medicare Advantage, and Medicaid managed care plans, so call the number on your member ID card to confirm your specific benefit.
Spravato vs. At-Home Ketamine: Why Coverage Differs
The FDA has approved only one ketamine-related medication for depression: esketamine, sold under the brand name Spravato. The FDA's 2019 approval requires esketamine to be administered under direct observation in a certified doctor's office or clinic, with the patient monitored for at least two hours afterward as part of the drug's Risk Evaluation and Mitigation Strategy (REMS) program. That in-person, monitored structure is what makes Spravato billable through standard medical insurance: the clinic submits a claim with a drug code and an administration code, and UHC can apply the same kind of medical necessity review it uses for other prescription drugs.
Generic, or racemic, ketamine, whether given by IV infusion in a clinic or prescribed as a take-home lozenge through a telehealth platform, is not FDA-approved for depression, anxiety, or any other psychiatric condition. It's prescribed off-label, meaning a licensed clinician judges it appropriate for a specific patient even though the FDA has only cleared ketamine itself as a surgical anesthetic. Off-label, self-administered use is the main reason UnitedHealthcare and most other major insurers, including Cigna and Blue Cross Blue Shield, decline to reimburse it.
What to Expect If You're Seeking Spravato Coverage Through UHC
If your prescriber is recommending Spravato rather than compounded ketamine, UnitedHealthcare plans generally require prior authorization before they'll pay. Your prescriber submits documentation showing you meet medical necessity criteria, which commonly includes a confirmed diagnosis of treatment-resistant depression, meaning you've tried and not responded to at least two different antidepressants at adequate doses and duration, and confirmation that Spravato will be given at a REMS-certified site rather than at home. Exact requirements vary by plan type: UHC commercial employer plans, UnitedHealthcare Medicare Advantage plans, and UnitedHealthcare Community Plan (Medicaid managed care) policies each set their own prior authorization rules and cost-sharing. If you're on Medicare, compare how traditional Medicare treats ketamine and esketamine separately in does Medicare cover ketamine therapy.
Because policies vary by state and plan and change over time, the only reliable way to confirm your own coverage is to call the member services number on your UHC insurance card, or log in to your member portal and search your Evidence of Coverage for "esketamine" or "Spravato." Ask the representative for the specific prior authorization criteria tied to your plan, not just a yes-or-no answer.
Compare your options
Move from the guide into a side-by-side comparison when you are ready to evaluate tradeoffs.
Compare optionsQuestions to Ask UnitedHealthcare Before You Start
- Confirm whether your plan covers esketamine (Spravato) and under which diagnosis codes
- Ask what prior authorization documentation your prescriber needs to submit
- Ask whether the specific clinic or REMS-certified site you plan to use is in-network
- Ask what your copay, coinsurance, and deductible will be for each Spravato visit
- Confirm whether compounded or at-home ketamine is covered under any circumstance
- Get the coverage answer in writing, or note the representative's name and reference number
If You're Considering an At-Home Telehealth Ketamine Program Instead
Most people who sign up with a telehealth ketamine clinic for depression or anxiety are using compounded, off-label ketamine that UnitedHealthcare will not reimburse, so plan to pay out of pocket for the consultation, the prescription, and ongoing monitoring. Review how much telehealth ketamine costs for typical price ranges, and check hidden fees in telehealth ketamine programs before you commit, since some platforms bill recurring membership or integration-session fees separately from the medication itself. Several clinics offer payment plans for ketamine therapy to spread out the cost, and you may be able to use an FSA or HSA for telehealth ketamine since it's a prescribed treatment, even when your insurance plan itself won't pay the claim. If you do receive a Spravato denial you believe was wrong, review your plan's appeals process and the steps in getting insurance reimbursement for ketamine therapy before you give up on coverage.
Important
Even patients who meet UnitedHealthcare's medical necessity criteria for Spravato cannot take the drug home. The FDA's REMS requirement mandates in-office administration and post-dose monitoring, so confirm the specific clinic or health system where you'd receive Spravato is in UHC's network before scheduling; out-of-network administration can trigger a separate, larger bill even when the drug itself is a covered benefit.
Compare Telehealth Ketamine Providers and Costs
See how pricing, payment options, and insurance acceptance compare across vetted telehealth ketamine providers before you choose one.
Frequently Asked Questions
Generally no. IV ketamine infusions for depression are off-label, so UHC typically does not treat them as a covered pharmacy or medical benefit, even when given in a licensed clinic. Coverage decisions can vary by plan, so confirm with UHC directly.
UnitedHealthcare Medicare Advantage plans can cover esketamine when medical necessity and prior authorization criteria are met, similar to how traditional Medicare handles the drug. See does Medicare cover ketamine therapy for how Part B and Part D rules differ.
Yes. UnitedHealthcare plans are required to offer an internal appeals process, and many states also allow an independent external review after that. Ask for the denial reason in writing, since it determines which appeal pathway applies.
Often yes. Ketamine treatment prescribed by a licensed clinician generally qualifies as an eligible medical expense for a flexible spending account (FSA) or health savings account (HSA), even if your insurance plan declines to pay the claim. Confirm specifics with your plan administrator; see using FSA/HSA for telehealth ketamine.
Share
Related Reading
Have a question about this topic?
Use the contact page when you need to send feedback, request a correction, or ask about the resource.